Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Boston Biomedical Research Institute (BBRI) was a non-profit institution concentrating on basic biomedical research to promote the understanding of human diseases (including heart disease, cancer, muscular dystrophy and Alzheimer's etc.). It was located in Watertown, Massachusetts.

TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. TILT is a preclinical stage company working in the field of cancer immunotherapy and will soon translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR-T therapy of solid tumors as currently achieved for CD19+ hematological tumors.

Humabs currently has two clinical-stage partnered programs, validating the CellClone technologies and generating a significant revenue stream Humabs has a broad partnership with MedImmune, the global biologics research and development arm of AstraZeneca, that covers multiple pathogens. The most advanced of the projects is an antibody directed against influenza A virus. This antibody, called MEDI8852, has demonstrated activity against all known subtypes of the influenza A virus and is therefore less affected by the emergence of new strains. The program was partnered with MedImmune while still in preclinical development and has currently concluded the clinical phase 1b/2a. Data on this program have been published in the journals Science and Cell. Humabs has also partnered with Novartis for an antibody directed against an undisclosed target. This program is currently in phase 2.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Changzhou Adam Biotechnology Co., Ltd., established on 2010-09-08, Business scope includes biomedicine,chemistry medicine,R&D and technical services of natural medicines;disinfection products,R&D and sales of cosmetics;Food research and development and sales(limit<food business license>Approved scope).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class I Medical Devices;Sales of Class II Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Tokyo Metropolitan Institute of Medical Science is a Japanese private company. The firm operates as a research institute that develops medicine.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Manufactures, marketes and imports, exports pharmaceutical drugs

Biotest Pharma GmbH engages in the manufacture and distribution of medicinal and pharmaceutical products. The company is headquartered in Dreieich, Germany.

Menarini Ricerche SpA provides research and development activities in the pharmaceutical sector. It involves in the full spectrum starting with the initial stages of research and the clinical trial phases up to industrial production as well as patent protection regulation. The company was founded in 1978 and is headquartered in Pomezia, Italy.

Hanwha Chemical Co., Ltd., a subsidiary of Hanwha Corp., is a company headquartered in the South Korea that manufactures chemical products.

Cetus Corporation was one of the first biotechnology companies. It was established in Berkeley, California in 1971, but conducted most of its operations in nearby Emeryville. Before merging with another company in 1991, it developed several significant pharmaceutical drugs as well as a revolutionary DNA amplification technique.